BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 32787737)

  • 1. Andrographolide enhanced radiosensitivity by downregulating glycolysis via the inhibition of the PI3K-Akt-mTOR signaling pathway in HCT116 colorectal cancer cells.
    Li X; Tian R; Liu L; Wang L; He D; Cao K; Ma JK; Huang C
    J Int Med Res; 2020 Aug; 48(8):300060520946169. PubMed ID: 32787737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PTPRH promotes the progression of non-small cell lung cancer via glycolysis mediated by the PI3K/AKT/mTOR signaling pathway.
    Wang S; Cheng Z; Cui Y; Xu S; Luan Q; Jing S; Du B; Li X; Li Y
    J Transl Med; 2023 Nov; 21(1):819. PubMed ID: 37974250
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LINC00941 promoted in vitro progression and glycolysis of laryngocarcinoma by upregulating PKM via activating the PI3K/AKT/mTOR signaling pathway.
    Li Z; Jin Q; Sun Y
    J Clin Lab Anal; 2022 Jul; 36(7):e24406. PubMed ID: 35588431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer.
    Moench R; Grimmig T; Kannen V; Tripathi S; Faber M; Moll EM; Chandraker A; Lissner R; Germer CT; Waaga-Gasser AM; Gasser M
    Oncotarget; 2016 Oct; 7(42):68749-68767. PubMed ID: 27626684
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [LncRNA SNHG11 promotes malignant progression of colorectal cancer cells through the PI3K/Akt/mTOR signaling pathway].
    Tao SN; Liu XC; Wang YY; Yang H
    Zhonghua Yi Xue Za Zhi; 2024 Mar; 104(10):758-765. PubMed ID: 38462356
    [No Abstract]   [Full Text] [Related]  

  • 6. The up-regulated lncRNA DLX6-AS1 in colorectal cancer promotes cell proliferation, invasion and migration via modulating PI3K/AKT/mTOR pathway.
    Zhang JJ; Xu WR; Chen B; Wang YY; Yang N; Wang LJ; Zhang YL
    Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8321-8331. PubMed ID: 31646562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Glut1 gene silencing on proliferation, differentiation, and apoptosis of colorectal cancer cells by targeting the TGF-β/PI3K-AKT-mTOR signaling pathway.
    Wu XL; Wang LK; Yang DD; Qu M; Yang YJ; Guo F; Han L; Xue J
    J Cell Biochem; 2018 Feb; 119(2):2356-2367. PubMed ID: 28884839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circ_100395 impedes malignancy and glycolysis in papillary thyroid cancer: Involvement of PI3K/AKT/mTOR signaling pathway.
    Chen L; Zhuo D; Yuan H
    Immunol Lett; 2022 Jun; 246():10-17. PubMed ID: 35447227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Elevated PDK1 Expression Drives PI3K/AKT/MTOR Signaling Promotes Radiation-Resistant and Dedifferentiated Phenotype of Hepatocellular Carcinoma.
    Bamodu OA; Chang HL; Ong JR; Lee WH; Yeh CT; Tsai JT
    Cells; 2020 Mar; 9(3):. PubMed ID: 32197467
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxyshikonin isolated from
    Zhu Y; Zhong Y; Long X; Zhu Z; Zhou Y; Ye H; Zeng X; Zheng X
    Pharm Biol; 2019 Dec; 57(1):412-423. PubMed ID: 31230505
    [No Abstract]   [Full Text] [Related]  

  • 11. Long noncoding RNA-JPX predicts the poor prognosis of ovarian cancer patients and promotes tumor cell proliferation, invasion and migration by the PI3K/Akt/mTOR signaling pathway.
    Li J; Feng L; Tian C; Tang YL; Tang Y; Hu FQ
    Eur Rev Med Pharmacol Sci; 2018 Dec; 22(23):8135-8144. PubMed ID: 30556851
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Inhibition effect of active fraction from clove on PI3K/Akt/mTOR signaling pathway to induce apoptosis of human colon cancer HCT116 cells].
    Zhao G; Zhang D; Yang XH; Li XF; Liu MH
    Zhongguo Zhong Yao Za Zhi; 2021 Mar; 46(5):1197-1204. PubMed ID: 33787115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KIAA0101 knockdown inhibits glioma progression and glycolysis by inactivating the PI3K/AKT/mTOR pathway.
    Wang K; Li J; Zhou B
    Metab Brain Dis; 2022 Feb; 37(2):489-499. PubMed ID: 34792707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acquisition of epithelial-mesenchymal transition and cancer stem cell phenotypes is associated with activation of the PI3K/Akt/mTOR pathway in prostate cancer radioresistance.
    Chang L; Graham PH; Hao J; Ni J; Bucci J; Cozzi PJ; Kearsley JH; Li Y
    Cell Death Dis; 2013 Oct; 4(10):e875. PubMed ID: 24157869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyanidin-3-glucoside suppresses the progression of lung adenocarcinoma by downregulating TP53I3 and inhibiting PI3K/AKT/mTOR pathway.
    Chen X; Zhang W; Xu X
    World J Surg Oncol; 2021 Aug; 19(1):232. PubMed ID: 34362378
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor suppressive effect of scavenger receptor class A member 5 overexpression in colorectal cancer by regulating PI3K/AKT/mTOR pathway.
    Li Y; Peng F; Tan X; Wang J; Xu Y
    Genes Genomics; 2021 Oct; 43(10):1189-1198. PubMed ID: 34417976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GOLPH3 inhibition reverses oxaliplatin resistance of colon cancer cells via suppression of PI3K/AKT/mTOR pathway.
    Yu T; An Q; Cao XL; Yang H; Cui J; Li ZJ; Xiao G
    Life Sci; 2020 Nov; 260():118294. PubMed ID: 32818544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P300 increases CSNK2A1 expression which accelerates colorectal cancer progression through activation of the PI3K-AKT-mTOR axis.
    Liu J
    Exp Cell Res; 2023 Sep; 430(1):113694. PubMed ID: 37391010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MicroRNA-7 inhibits colorectal cancer cell proliferation, migration and invasion via TYRO3 and phosphoinositide 3-kinase/protein B kinase/mammalian target of rapamycin pathway suppression.
    Qin A; Qian W
    Int J Mol Med; 2018 Nov; 42(5):2503-2514. PubMed ID: 30226533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma.
    Makinoshima H; Takita M; Saruwatari K; Umemura S; Obata Y; Ishii G; Matsumoto S; Sugiyama E; Ochiai A; Abe R; Goto K; Esumi H; Tsuchihara K
    J Biol Chem; 2015 Jul; 290(28):17495-504. PubMed ID: 26023239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.